The project of Common Structure of Research between the INSERM UMR 1229-RMES, "Regenerative medicine and skeleton" and the HTL Company join in a shared commitment to develop hydrogels for the pharmaceutical industry, the tissue engineering and the assisted cellular therapy. These two structures work together for 2 years on a first application of implementation of a new method of reticulation of hyaluronic acid (patents technology of RMeS).They objectified the need and the necessity of building together a common laboratory to meet the expectations and the needs for both structures: • For the Research Lab RMeS, which finalizes silanized hydrogels since twenty years with more than about ten potential applications, this association is an opportunity to obtain a production of its molecules in conditions respecting cGMP to plan the first clinical trials in the field of the skeleton and the cardiology. It is also a way to go up to the end of the scientific and valorization strategies imagined to concretize them in phase 1 trial to propose them to patients. • For HTL Company, the challenge is to develop new strategies of innovative productions of viscous solutions and hydrogels to position themselves in the market of medical devices and regenerative medicine. Indeed at the moment HTL products only raw materials for industries which develop medical applications. From an operational point of view, HTL Company is a pharmaceutical company specialized in the production of polysaccharides of interests for health and products molecules which interest particularly RMeS for its research projects in regenerative medicine of the skeleton. RMeS controls a chemistry of spontaneous reticulation of polysaccharides without any reticulation agents, allowing the realization of biocompatible hydrogels loaded with cells of bioactive factors. Furthermore RMeS is one French Lab specialized in regenerative medicine of skeleton, bone, periodontium, cartilage, arthritis and intervertebral disc. RMeS, thanks to its visibility on hydrogels for the encapsulation of cells and on biomaterials has scientific collaborations in the fields of diabetes, liver, heart, nervous system and colon what will allow HTL Company to intend to participate in these scientific adventures by supplying synthetic extracellular matrices constituted of hydrogels. The LabCom GELMECS is the basis of future academic and industrial consortium which can open on numerous collaborations and applications in gestation thanks to others collaborations RMeS / Industries on already existing applications.